TrianglePUBLICATIONS · 28339824
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Neuro Oncol
- Publication date
- 2017 Aug 1
- First author
- Banerjee A
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Banerjee A
- type
- Author
- name
- Jakacki RI
- type
- Author
- name
- Onar-Thomas A
- type
- Author
- name
- Wu S
- type
- Author
- name
- Nicolaides T
- type
- Author
- name
- Young Poussaint T
- type
- Author
- name
- Fangusaro J
- type
- Author
- name
- Phillips J
- type
- Author
- name
- Perry A
- type
- Author
- name
- Turner D
- type
- Author
- name
- Prados M
- type
- Author
- name
- Packer RJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Banerjee A
- type
- Author
- name
- Jakacki RI
- type
- Author
- name
- Onar-Thomas A
- type
- Author
- name
- Wu S
- type
- Author
- name
- Nicolaides T
- type
- Author
- name
- Young Poussaint T
- type
- Author
- name
- Fangusaro J
- type
- Author
- name
- Phillips J
- type
- Author
- name
- Perry A
- type
- Author
- name
- Turner D
- type
- Author
- name
- Prados M
- type
- Author
- name
- Packer RJ
- type
- Author
- bibliography ids
- nci-bib-484f93293fb28106187db4d3
- book metadata
- content sha256
- d8da28cac180f00c95ad943f2bb5d8b2ea1e9f34ee915fee692230a6585ae918
- document type
- citation
- dois
- 10.1093/neuonc/now282
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:28339824
- immutable id
- pubmed:28339824@d8da28cac180f00c95ad943f2bb5d8b2ea1e9f34ee915fee692230a6585ae918
- journal
- abbreviation
- Neuro Oncol
- issn electronic
- 1523-5866
- issn print
- 1522-8517
- issue
- 8
- name
- Neuro-oncology
- nlm unique id
- 100887420
- pages
- 1135-1144
- volume
- 19
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 28339824
- provenance
- batch id
- 7a1288ac8bb5f9826304
- provider
- NCBI PubMed ESummary
- record sha256
- 52a4d273362d37d670939d53e6a232d2483a869d91767c4ee338d5fa67200965
- response sha256
- 0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
- retrieved at
- 2026-09-09T23:47:23.138359+00:00
- publication date
- display
- 2017 Aug 1
- precision
- day
- year
- 2017
- publication types
- Clinical Trial, Phase I
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Preserved source evidence · Not medical advice